Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · Real-Time Price · USD
0.292
-0.005 (-1.75%)
At close: Nov 4, 2024, 4:00 PM
0.291
-0.001 (-0.45%)
After-hours: Nov 4, 2024, 7:19 PM EST

Company Description

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States.

The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.

The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.

Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Cara Therapeutics, Inc.
Cara Therapeutics logo
Country United States
Founded 2004
IPO Date Jan 31, 2014
Industry Biotechnology
Sector Healthcare
Employees 55
CEO Christopher Posner

Contact Details

Address:
400 Atlantic Street, Suite 500
Stamford, Connecticut 06901
United States
Phone 203 406 3700
Website caratherapeutics.com

Stock Details

Ticker Symbol CARA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001346830
CUSIP Number 140755109
ISIN Number US1407551092
SIC Code 2834

Key Executives

Name Position
Christopher A. Posner President, Chief Executive Officer and Director
Ryan D. Maynard Chief Financial Officer
Dr. Derek T. Chalmers D.Sc., Ph.D. Co-Founder and Senior Advisor
Scott M. Terrillion Chief Compliance Officer, General Counsel and Corporate Secretary
Matthew Murphy Manager of Investor Relations

Latest SEC Filings

Date Type Title
Oct 30, 2024 SC 13D General statement of acquisition of beneficial ownership
Aug 14, 2024 10-Q Quarterly Report
Aug 1, 2024 8-K Current Report
Jul 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jun 18, 2024 8-K Current Report
Jun 12, 2024 8-K Current Report
Jun 7, 2024 424B5 Filing
Jun 7, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report
May 13, 2024 8-K Current Report